1-303-522-8502 
:
CLDN18.2 Overexpressing Cell Lines
CLDN18.2 Overexpressing Cell Lines
Pre-Validated Cellular Tools for Targeted Cancer Therapy & Immuno-Oncology Research
About This Collection
Precision Tools for a High-Potential Target
Claudin 18.2 (CLDN18.2) has emerged as a highly promising, tumor-selective antigen for next-generation targeted therapies, including monoclonal antibodies, bispecifics, antibody-drug conjugates (ADCs), and CAR-T cells. Reliable and consistent preclinical models are essential to drive this innovation.
This featured collection from RunToGen comprises a panel of stable human and murine cell lines engineered to overexpress CLDN18.2, either alone or in combination with other key immuno-oncology targets like PD-L1.
Key Advantages of This Panel:
Featured CLDN18.2 Cell Line Products
Click "View Details" for comprehensive specifications, validation data, and ordering information for each product.
| Product Name | Catalog # | Host & Key Features | Size | Product Details |
|---|---|---|---|---|
|
Raji Human CLDN18.2 Overexpressing Cell Line
|
RG-1600 |
Host: Raji (Human Lymphoma)
Engineered for high CLDN18.2 expression in a B-cell background.
|
2×10⁶ cells/vial | View Details |
|
NCI-N87-CLDN18.2 Overexpressing Cell Line
|
RG-855 |
Host: NCI-N87 (Human Gastric Carcinoma)
Human model line for in vivo efficacy studies of human CLDN18.2-targeting agents.
|
2×10⁶ cells/vial | View Details |
|
MKN45-CLDN18.2 Overexpressing Cell Line
|
RG-1266 |
Host: MKN45 (Human Gastric Carcinoma)
Human overexpression of CLDN18.2 in a clinically relevant gastric cancer line.
|
5×10⁶ cells/vial | View Details |
|
NCI-N87-CLDN18.2-PDL1 Overexpressing Cell Line
|
RG-1459 |
Host: NCI-N87 (Human Gastric Carcinoma)
A standard gastric cancer model co-expressing CLDN18.2 and the immune checkpoint PD-L1.
|
5×10⁶ cells/vial | View Details |
|
MC38-PDL1-CLDN18.2-OS8 Overexpressing Cell Line
|
RG-1452 |
Host: MC38 (Mouse Colon Carcinoma)
Murine syngeneic model for immunotherapy, expressing PD-L1, OS38 and CLDN18.2.
|
5×10⁶ cells/vial | View Details |
|
NUGC4-CLDN18.2 overexpressing cell
|
RG-856 |
Host: NUGC4 (Human Gastric Carcinoma)
Engineered NUGC4 for CLDN18.2-targeted therapy development.
|
5×10⁶ cells/vial | View Details |
|
HuCCT1-CLDN18.2-High Overexpressing Cell Line
|
RG-1417 |
Host: HuCCT1 (Human Cholangiocarcinoma)
High-expression clone in a bile duct cancer model, useful for potency assays.
|
5×10⁶ cells/vial | View Details |
|
HUCCT1-CLDN18.2-Low Overexpressing Cell Line
|
RG-1418 |
Host: HuCCT1 (Human Cholangiocarcinoma)
Low-expression counterpart, ideal for assessing sensitivity and binding affinity.
|
5×10⁶ cells/vial | View Details |
|
KATOIII-CLDN18.2 Overexpressing Cell Line
|
RG-846 |
Host: KATOIII (Human Gastric Carcinoma)
KATOIII gastric cancer cell line engineered to overexpress the CLDN18.2 target protein for therapeutic screening.
|
5×10⁶ cells/vial | View Details |
Key Research & Development Applications
Therapeutic Antibody Screening
Use these lines for primary binding assays, epitope binning, and affinity ranking of novel anti-CLDN18.2 monoclonal or bispecific antibodies.
ADC & Cytotoxicity Testing
Quantify the internalization, payload delivery, and direct cell-killing efficacy of CLDN18.2-targeting antibody-drug conjugates.
CAR-T Cell Validation
Validate the specificity, activation, and cytotoxic potency of CLDN18.2-directed CAR-T cells in vitro and in vivo (using murine lines).
Combination Therapy Studies
Leverage PD-L1/CLDN18.2 dual-expressing lines to investigate synergy between targeted therapies and immune checkpoint inhibitors.
Ready to Accelerate Your CLDN18.2 Research?
Access our complete collection of validated cell lines and get expert support for your immuno-oncology projects. Streamline your therapeutic development with reliable, reproducible models.
Technical Support
Dedicated scientific support team to assist with experimental design and troubleshooting.
Bulk Order Discounts
Special pricing for large orders and collaborative research projects.
Custom Engineering
Need a specific modification? Inquire about custom cell line development services.
Quality Guarantee: All cell lines are validated for CLDN18.2 expression, mycoplasma-free, and backed by our quality assurance protocol.
